Low-dose CT chest (LDCT)

Low-dose computed tomography (LDCT) is a type of imaging test that uses X-rays to create detailed pictures of the lungs and can help detect early signs of lung cancer, making it crucial for preventive health care.

Indexed studies indicate that LDCT screening reduces lung cancer-related deaths among high-risk groups such as heavy smokers. Research also shows its potential benefits extend to never-smokers with a family history of lung cancer. Studies on using LDCT for diagnosing and managing COVID-19 have highlighted its effectiveness in imaging pneumonia related to the virus, though radiation dose management remains important.

This test is closely linked to lung cancer screening programs and can be part of follow-up care after detecting pulmonary nodules or other abnormalities. It also connects with deep learning models that assess lung cancer risk based on CT images.

While evidence supports LDCT's benefits in specific populations, more research is needed to fully understand its effectiveness across broader demographics.

Sources

• Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. (PMID:35921047)
• Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. (PMID:38042167)
• Low-Dose Chest CT Protocols for Imaging COVID-19 Pneumonia: Technique Parameters and Radiation Dose. (PMID:37109522)
• Low Dose Chest CT and Lung Ultrasound for the Diagnosis and Management of COVID-19. (PMID:34069557)
• External Testing of a Deep Learning Model for Lung Cancer Risk from Low-Dose Chest CT. (PMID:40762850)
• Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test. (PMID:33793424)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._